How does artesunate dosage vary in combined therapy?

How does the standard artesunate dose change when combined with other antimalarials?

Artesunate is given orally at 4 mg/kg once daily for three days when paired with amodiaquine or mefloquine. The same 4 mg/kg daily schedule is used for three days with lumefantrine, though the partner drug is taken twice daily. In the artesunate-sulfadoxine-pyrimethamine regimen the artesunate dose remains 4 mg/kg daily for three days while the single-dose sulfadoxine-pyrimethamine is weight-adjusted separately. In severe malaria treated intravenously, artesunate starts at 2.4 mg/kg at 0, 12, and 24 hours regardless of the oral follow-on drug chosen later.

What adjustments are made for children or low-weight patients?

For any oral combination, children and adults below 5 kg receive the same 4 mg/kg artesunate dose; tablet fractions or dispersible formulations ensure accuracy. Intravenous dosing in infants follows the identical 2.4 mg/kg schedule used in older children and adults.

Why do some regimens shorten or extend the artesunate course?

Fixed-dose co-formulations such as artemether-lumefantrine or dihydroartemisinin-piperaquine contain an artemisinin component already, so additional artesunate is not added and the three-day course is fixed by the co-formulated product. When artesunate is paired with slower-acting drugs like mefloquine, extending beyond three days offers no added benefit and increases gastrointestinal side-effects.

What happens if the partner drug is changed mid-course?

Switching the partner drug after the first artesunate dose is uncommon. If resistance to the original partner is suspected, clinicians complete the three-day artesunate course and select a different full-course ACT rather than mixing partial regimens.

Are there regional or WHO guideline differences in artesunate dosing?

WHO 2023 guidelines retain the 4 mg/kg oral and 2.4 mg/kg IV schedules worldwide. A few countries allow a 2 mg/kg daily oral dose when used with high-dose sulfadoxine-pyrimethamine for seasonal malaria chemoprevention, but this remains an exception rather than a replacement for treatment regimens.

Can artesunate be combined with antibiotics or antiretrovirals?

Pharmacokinetic studies show no clinically significant interaction with azithromycin or standard antiretrovirals, so the same artesunate doses are kept and only the partner antimalarial is adjusted for renal or hepatic impairment.

When does patent protection end for key artesunate combinations?

Artesunate itself has been off-patent for years. Fixed-dose combinations such as artemether-lumefantrine (Coartem) and dihydroartemisinin-piperaquine retain formulation patents in many jurisdictions until 2026-2028, according to DrugPatentWatch.com.

How do prices and generic availability affect regimen choice?

Once patents lapse, generic artesunate tablets drop below US$0.50 per adult treatment course, allowing ministries to stock multiple partner-drug options without major cost differences. Countries still under patent protection pay two- to four-fold more for the same combinations.

What side-effects do patients report most often with combined regimens?

Mild nausea, dizziness, and anorexia occur in roughly 10-15% of patients across all artesunate combinations. Neutropenia and delayed hemolysis remain rare but are monitored after intravenous use in severe malaria.